Valuation: BACHEM HOLDING AG

Market Cap 5.9B 7.1B 6.31B 5.38B 10.12B 684B 10.26B 71.39B 27.64B 348B 26.67B 26.1B 1,119B P/E 2026 *
32.3x
P/E 2027 * 25.3x
Enterprise Value 6.26B 7.54B 6.7B 5.71B 10.75B 726B 10.9B 75.79B 29.34B 370B 28.32B 27.7B 1,188B EV / Sales 2026 *
6.66x
EV / Sales 2027 * 5.61x
Free-Float
99.67%
Yield 2026 *
1.28%
Yield 2027 * 1.45%
Manager TitleAgeSince
Chief Executive Officer 52 2025-12-31
Director of Finance/CFO 49 2021-01-31
Chief Operating Officer - 2025-08-31
Director TitleAgeSince
Director/Board Member 53 2011-04-12
Chairman 70 2012-04-24
Director/Board Member 57 2014-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 7.1B
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.09%-1.51%+24.46%+78.24% 59.26B
+1.09%-1.05%+3.83%+33.94% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.83%+29.52%+22.61% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.48%-0.52%+52.77%+154.01% 43.6B
Weighted average by Cap. +0.02%-0.32%+57.95%+145.69%

Financials

2026 *2027 *
Net sales 940M 1.13B 1.01B 857M 1.61B 109B 1.64B 11.38B 4.4B 55.51B 4.25B 4.16B 178B 1.16B 1.4B 1.24B 1.06B 1.99B 135B 2.02B 14.06B 5.44B 68.61B 5.25B 5.14B 220B
Net income 183M 221M 196M 167M 314M 21.23B 319M 2.22B 858M 10.81B 828M 810M 34.73B 230M 277M 246M 210M 395M 26.68B 400M 2.78B 1.08B 13.59B 1.04B 1.02B 43.64B
Net Debt 364M 438M 389M 331M 624M 42.15B 632M 4.4B 1.7B 21.46B 1.64B 1.61B 68.94B 622M 749M 665M 567M 1.07B 72.09B 1.08B 7.52B 2.91B 36.71B 2.81B 2.75B 118B
Logo BACHEM HOLDING AG
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-